Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

StockNews.com upgraded shares of Eli Lilly and Company (NYSE:LLY – Free Report) from a hold rating to a buy rating in a research report report published on Wednesday morning. A number of other ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) dropped 0.6% on Tuesday . The company traded as low as $767.25 and last traded at $768.83. Approximately 348,052 shares traded hands during ...

Novon Nordisk's Ozempic/Wigobi, a glucagon-like peptide-1 (GLP-1) injection, and Eli Lilly's Mounjaro/Jebbound have been ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Next in line is Eli Lilly, which could have results from a cardiovascular outcomes trial of its own this year. Lilly’s trial ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.